As of 12:42pm ET
| -0.0599 / -2.49%|
Pluristem Therapeutics, Inc. is a bio-therapeutic company, which develops standardized cell therapy products for the treatment of life threatening diseases. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. It offers to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. Pluristem Therapeutics develops pipeline of products derived from human placenta, a non-controversial, non-embryonic, adult stem cell source. It intends to commercialize cell therapy production technologies and products. The company operates in Israel and United States of America. Pluristem Therapeutics was founded on May 11, 2001 and is headquartered in Haifa, Israel.
|Zami Aberman||Chairman & Chief Executive Officer|
|Yaky Yanay||President & Chief Operating Officer|
|Boaz Gur-Lavie||Chief Financial Officer & Secretary|
|Racheli Ofir||Vice President-Research & Intellectual Property|
|Esther Lukasiewicz-Hagai||Vice President-Clinical & Medical Affairs|